Cargando…
Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study
BACKGROUND: Catheter-directed thrombolysis (CDT) has been an important therapy and seems effective in patients with splanchnic venous thrombosis (SVT) secondary to some diseases, but this intervention hasn’t been formally evaluated in the setting of acute pancreatitis (AP). METHODS: This was a retro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339537/ https://www.ncbi.nlm.nih.gov/pubmed/37438694 http://dx.doi.org/10.1186/s12893-023-02046-y |
_version_ | 1785071866626441216 |
---|---|
author | Zhang, Zongwen Gao, Lin Liu, Zirui Li, Gang Ye, Bo Zhou, Jing Ke, Lu Tong, Zhihui Li, Weiqin |
author_facet | Zhang, Zongwen Gao, Lin Liu, Zirui Li, Gang Ye, Bo Zhou, Jing Ke, Lu Tong, Zhihui Li, Weiqin |
author_sort | Zhang, Zongwen |
collection | PubMed |
description | BACKGROUND: Catheter-directed thrombolysis (CDT) has been an important therapy and seems effective in patients with splanchnic venous thrombosis (SVT) secondary to some diseases, but this intervention hasn’t been formally evaluated in the setting of acute pancreatitis (AP). METHODS: This was a retrospective study enrolled patients between January 2013 and December 2018. AP patients who developed SVT-induced symptoms, including intractable ascites and/or enteral nutrition intolerance, were included. Demographics, SVT associated parameters, clinical features and outcomes, long-term quality of life evaluated by using SF-36 questionnaire were compared between CDT group and systemic anticoagulation (SAC) group. RESULTS: 6 patients underwent CDT and 17 received SAC. Patients in CDT group had a higher recanalization rate (100% versus 35.3%; p = 0.014) and shorter time to symptoms resolution (median 8 days versus. 31.5 days, p = 0.004). Mortality and length of hospital stay were comparable between two groups. The association analysis indicated that CDT use exerted a significantly beneficial effect on recanalization rate (risk ratio, 2.833; 95% CI, 1.489 to 5.393; p = 0.002) and time to symptoms resolution (mean difference, -33.333; 95% CI, -64.612 to -2.055; p = 0.038). No SVT-related symptoms recurrence was recorded in survivors at six-month follow-up. There was no statistical difference in either item of SF-36 questionnaire between two groups. CONCLUSIONS: Compared with SAC, CDT may facilitate vascular recanalization and shorten symptom resolution for symptomatic SVT. |
format | Online Article Text |
id | pubmed-10339537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103395372023-07-14 Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study Zhang, Zongwen Gao, Lin Liu, Zirui Li, Gang Ye, Bo Zhou, Jing Ke, Lu Tong, Zhihui Li, Weiqin BMC Surg Research BACKGROUND: Catheter-directed thrombolysis (CDT) has been an important therapy and seems effective in patients with splanchnic venous thrombosis (SVT) secondary to some diseases, but this intervention hasn’t been formally evaluated in the setting of acute pancreatitis (AP). METHODS: This was a retrospective study enrolled patients between January 2013 and December 2018. AP patients who developed SVT-induced symptoms, including intractable ascites and/or enteral nutrition intolerance, were included. Demographics, SVT associated parameters, clinical features and outcomes, long-term quality of life evaluated by using SF-36 questionnaire were compared between CDT group and systemic anticoagulation (SAC) group. RESULTS: 6 patients underwent CDT and 17 received SAC. Patients in CDT group had a higher recanalization rate (100% versus 35.3%; p = 0.014) and shorter time to symptoms resolution (median 8 days versus. 31.5 days, p = 0.004). Mortality and length of hospital stay were comparable between two groups. The association analysis indicated that CDT use exerted a significantly beneficial effect on recanalization rate (risk ratio, 2.833; 95% CI, 1.489 to 5.393; p = 0.002) and time to symptoms resolution (mean difference, -33.333; 95% CI, -64.612 to -2.055; p = 0.038). No SVT-related symptoms recurrence was recorded in survivors at six-month follow-up. There was no statistical difference in either item of SF-36 questionnaire between two groups. CONCLUSIONS: Compared with SAC, CDT may facilitate vascular recanalization and shorten symptom resolution for symptomatic SVT. BioMed Central 2023-07-12 /pmc/articles/PMC10339537/ /pubmed/37438694 http://dx.doi.org/10.1186/s12893-023-02046-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Zongwen Gao, Lin Liu, Zirui Li, Gang Ye, Bo Zhou, Jing Ke, Lu Tong, Zhihui Li, Weiqin Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title | Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title_full | Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title_fullStr | Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title_full_unstemmed | Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title_short | Catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
title_sort | catheter-directed thrombolysis versus systemic anticoagulation in the treatment of symptomatic splanchnic venous thrombosis secondary to acute pancreatitis: a retrospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339537/ https://www.ncbi.nlm.nih.gov/pubmed/37438694 http://dx.doi.org/10.1186/s12893-023-02046-y |
work_keys_str_mv | AT zhangzongwen catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT gaolin catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT liuzirui catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT ligang catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT yebo catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT zhoujing catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT kelu catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT tongzhihui catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy AT liweiqin catheterdirectedthrombolysisversussystemicanticoagulationinthetreatmentofsymptomaticsplanchnicvenousthrombosissecondarytoacutepancreatitisaretrospectivecohortstudy |